The enhancement of airway remodeling by IL-17 has been confirmed in murine models of asthma in which its blockade by anti-IL-17 antibodies or genetic deficiency reduced mucus hypersecretion, goblet cell hyperplasia, subepithelial collagen deposition and airway smooth muscle layer thickening together with airway neutrophilia (118, 119). The gene discussed is IL17A; the disease is asthma.